Literature DB >> 12759093

Maternal drug use in early pregnancy and infant cardiovascular defect.

Bengt A J Källén1, Petra Otterblad Olausson.   

Abstract

The purpose of the paper is to identify maternal drug use that may be associated with an increased risk for cardiac defects in the offspring. A case-control study was performed with cases (cardiovascular defects without known chromosome anomalies) being identified from three Swedish health registers (n=5015) and controls being all infants born in Sweden during the period 1 July 1995-2001 (n=577,730). Information on drug exposure was obtained by interview in early pregnancy. Associations between maternal drug use and infant cardiovascular defect were identified for insulin, antihypertensives, fertility drugs, erythromycin, naproxen, anticonvulsants, nitrofurantoin, clomipramine, and budesonide in nasal preparations. Some of these associations are probably due to confounding from underlying disease or complaint, some may be due to multiple testing, some may be true drug effects. Further studies are needed to verify or reject these associations.

Entities:  

Mesh:

Year:  2003        PMID: 12759093     DOI: 10.1016/s0890-6238(03)00012-1

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  45 in total

1.  [Medication therapy during pregnancy].

Authors:  S Gronau; A Neumann
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

Review 2.  Getting to the heart of the matter: epidemiology of cyanotic heart defects.

Authors:  Jennifer L Kornosky; Hamisu M Salihu
Journal:  Pediatr Cardiol       Date:  2008-01-10       Impact factor: 1.655

Review 3.  Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.

Authors:  Cynthia M Nijenhuis; Peter G J ter Horst; Lolkje T W de Jong-van den Berg; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  Fetal safety of macrolides.

Authors:  Anat Bahat Dinur; Gideon Koren; Ilan Matok; Arnon Wiznitzer; Elia Uziel; Rafael Gorodischer; Amalia Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study.

Authors:  Brian T Bateman; Krista F Huybrechts; Michael A Fischer; Ellen W Seely; Jeffrey L Ecker; Anna S Oberg; Jessica M Franklin; Helen Mogun; Sonia Hernandez-Diaz
Journal:  Am J Obstet Gynecol       Date:  2014-09-28       Impact factor: 8.661

Review 6.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

7.  Counseling pregnant women treated with paroxetine. Concern about cardiac malformations.

Authors:  Adrienne Einarson; Gideon Koren
Journal:  Can Fam Physician       Date:  2006-05       Impact factor: 3.275

Review 8.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

9.  A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.

Authors:  D N Bateman; P R McElhatton; D Dickinson; C Wren; J N S Matthews; M O'Keeffe; S H L Thomas
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

10.  Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

Authors:  K Nezvalová-Henriksen; O Spigset; H Nordeng
Journal:  BJOG       Date:  2013-03-14       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.